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Diffusion tensor imaging (DTI) has revealed white matter abnormalities in individuals with
attention-deﬁcit/hyperactivity disorder (ADHD). Stimulant treatment may affect such abnorm-
alities. The current study investigated associations between long-term stimulant treatment and
white matter integrity within the frontal-striatal and mesolimbic pathways, in a large sample of
children, adolescents and young adults with ADHD. Participants with ADHD (N=172; mean age
17, range 9–26) underwent diffusion-weighted MRI scanning, along with an age- and gender-
matched group of 96 control participants. Five study-speciﬁc white matter tract masks
(orbitofrontal-striatal, orbitofrontal-amygdalar, amygdalar-striatal, dorsolateral-prefrontal-
striatal and medialprefrontal- striatal) were created. First we analyzed case-control differ-
ences in fractional anisotropy (FA) and mean diffusivity (MD) within each tract. Second, FA and
MD in each tract was predicted from cumulative stimulant intake within the ADHD group. After
correction for multiple testing, participants with ADHD showed reduced FA in the orbitofrontal-
striatal pathway (p=0.010, effect size=0.269). Within the ADHD group, higher cumulative
stimulant intake was associated with lower MD in the same pathway (p=0.011, effect
size=0.164), but not with FA. The association between stimulant treatment and
orbitofrontal-striatal MD was of modest effect size. It fell short of signiﬁcance after addingo.2016.02.007
CNP. All rights reserved.
edisch Centrum Groningen, Dept. Of Psychiatry, Huispostcode CC10, 9700 VB Groningen, The
ax: +31 50 361 93 90.
cg.nl (L.J.S. Schweren).
675Stimulant treatment history predicts frontal-striatal structural connectivity in adolescentsADHD severity or ADHD type to the model (p=0.036 and p=0.094, respectively), while the
effect size changed little. Our ﬁndings are compatible with stimulant treatment enhancing
orbitofrontal-striatal white matter connectivity, and emphasize the importance of the
orbitofrontal cortex and its connections in ADHD. Longitudinal studies including a drug-naïve
baseline assessment are needed to distinguish between-subject variability in ADHD severity
from treatment effects.
& 2016 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Diffusion tensor imaging (DTI) has revealed abnormalities in
white matter integrity, or structural connectivity, in individuals
with attention-deﬁcit/hyperactivity disorder (ADHD) (for exten-
sive reviews, see Van Ewijk et al., 2012; Konrad and Eickhoff,
2010). Multiple parameters of white matter integrity can be
derived from DTI, including fractional anisotropy (FA) and mean
diffusivity (MD). FA measures directionality of water diffusion
and is typically high in organized structures such as densely
packed white matter bundles, as water is more likely to diffuse
along the axons rather than perpendicular to the axons. MD
measures the amount of water diffusion in any direction and is
high in areas with few natural barriers to water diffusion, such
as the ventricles. Less commonly reported are axial diffusivity
(AD; measuring water diffusion along the main diffusion direc-
tion) and radial diffusivity (RD; measuring water diffusion
perpendicular to the main diffusion direction). It is important
to note that the interpretation of altered diffusion parameters
is complex, especially in psychiatric disorders where changes
are mostly subtle. Increased MD and decreased FA are often
regarded as indications of impaired or decreased structural
connectivity (Thomason and Thompson, 2011), but the neuro-
pathological processes underlying such changes are largely
unknown (Jones et al., 2013).
To date, ﬁndings on structural connectivity in individuals with
ADHD compared to healthy controls have been mixed. Whereas
some studies reported decreased FA and/or increased MD in
individuals with ADHD compared to controls (Ashtari et al.,
2005; Cao et al., 2010; Hamilton et al., 2008; Pavuluri et al.,
2009), suggesting decreased structural connectivity in ADHD,
others found increased FA and/or decreased MD (Li et al., 2010;
Peterson et al., 2011; Silk et al., 2009b). Null ﬁndings of no
changes in structural connectivity have also been reported (Silk
et al., 2009a, 2009b). In recent work from our group, van Ewijk
et al. found widespread FA reduction in both participants with
ADHD and their unaffected siblings, compared to healthy
control participants, suggesting that reduced FA may represent
a genetic vulnerability to ADHD. In addition, higher FA and
lower MD were observed in more severely affected compared to
less severely affected individuals with ADHD, which may reﬂect
a second, distinct, mechanism associated with ADHD symptom
severity (Van Ewijk et al., 2014). Inconsistent ﬁndings in
previous studies may partially be explained by these two
seemingly opposing mechanisms being at play.
Inconsistent ﬁndings may also reﬂect differences
between the ADHD samples with regard to stimulant treat-
ment history. Individuals with ADHD often take stimulants
for prolonged periods of time. Studies investigating long-term stimulant treatment effects on brain structure have
almost exclusively focused on gray matter and/or subcor-
tical structures. Several such studies (but not all) have
suggested structural normalization with long-term stimulant
treatment (Nakao et al., 2011; Shaw et al., 2009; Sobel
et al., 2010), i.e. abnormalities typically associated with
ADHD were smaller or absent in individuals with ADHD who
had been treated with stimulants. Stimulant-induced
changes in gray matter might be accompanied by changes
in white matter.
Only few studies have explored long-term stimulant
effects on white matter integrity quantiﬁed by DTI in
individuals with ADHD. One study applied deterministic
tractography to delineate the frontal-striatal tracts, and
compared average FA within these tracts between children
with a relatively short versus a relatively long history of
stimulant treatment (De Zeeuw et al., 2012). No differences
between the two groups were detected. Small sample size
(n=13 per group) and using average FA across all frontal-
striatal tracts as the primary outcome measure limits the
interpretation of this negative ﬁnding. A second study used
both tract-based spatial statistics (TBSS) and whole-brain
deterministic tractography, to perform a hypothesis-free
search for differences in FA or MD between young
treatment-naïve children with ADHD, children with ADHD
who had been treated with stimulants, and healthy control
children (n=16, n=24, and n=26, respectively) (De Luis-
García et al., 2015). Stimulant treatment was associated
with decreased MD in several major white matter bundles,
including the uncinate fasciculus connecting the medial
temporal limbic structures to the orbitofrontal cortex.
Importantly, differences in pre-treatment ADHD severity
between children with and without stimulant treatment
were not assessed, and may have confounded results. In a
prior study of our own group on the association between
structural connectivity and symptom severity, results did
not change when history of stimulant treatment (treated/
untreated) was taken into account (Van Ewijk et al., 2014).
In the current report, we investigated the association
between stimulant treatment history and structural con-
nectivity in a large sample of children, adolescents and
young adults with ADHD. This investigation adds to the
previous study from our group in two ways. First, in the
current study we assessed stimulant treatment history to
detail, and performed dimensional analyses of lifetime
cumulative stimulant dose. Second, we applied a sensitive
hypothesis-driven region-of-interest (ROI) approach based
on the dopaminergic working mechanism of stimulants.
Stimulants generate their clinical effects, at least partially,
L.J.S. Schweren et al.676by enhancing dopaminergic neurotransmission in the stria-
tum (Volkow et al., 2012). Two major dopaminergic path-
ways connect the striatum to other brain regions: the
frontal-striatal pathway, connecting the striatum to the
medial and dorsolateral prefrontal cortex; and the meso-
limbic pathway, connecting the striatum to the limbic
system including the amygdala and orbitofrontal cortex.
We used probabilistic tractography to quantify white matter
microstructure within these pathways. A healthy control
group was included for reference. We hypothesized that
participants with ADHD would present with reduced FA and/
or increased MD in frontal-striatal pathways, indicative of
lower structural connectivity. Second, in line with observa-
tions of gray matter structural normalization with stimulant
treatment, we hypothesized that FA would be higher and MD
would be lower (both indicative of enhanced structural
connectivity) in participants with a history of high cumula-
tive stimulant intake, compared to those with a history of
no or less stimulant intake.2. Experimental procedures
2.1 Participants
An ADHD and control sample were selected from the NeuroIMAGE
cohort, a family-based cohort that includes 415 families with one or
more probands with ADHD, as well as 141 healthy control families
(Von Rhein et al., 2014). For inclusion, participants had to meet the
following criteria: (1) age between 8 and 30 years old, (2) IQ470,
(3) no diagnosis of epilepsy, general learning difﬁculties, or known
genetic disorders, and (4) availability of a good quality diffusion
scan and T1 structural scan. Participants with ADHD had to meet
diagnostic criteria for ADHD (see below). The following additional
inclusion criteria applied to healthy control participants: (1) no past
or present mental health care utilization, (2) no past or present
psychiatric disorders (ADHD or otherwise) in ﬁrst-degree relatives,
and (3) no past or present psychoactive medication use reported by
either the pharmacy or the participant/parents (incidental use was
allowed). All subjects who did not fulﬁll criteria for either the ADHD
or the control group were excluded, thus excluding unaffected
siblings of individuals with ADHD. A group-matched (on age, gender,
and scanner location) healthy control sample was drawn. The ﬁnal
sample consisted of 172 participants with ADHD and 96 healthy
control participants (for reference), between the ages of nine and
26 years (M=17.2, SD=3.1). Informed consent was signed by all
participants (parents signed informed consent for participants
under 12 years of age) and their parents (for participants under
18 years of age), and the study was approved by the ethical
committees of participating institutions.2.2 Diagnostic assessment
All participants were assessed using a combination of a semi-
structured diagnostic interview and Conners' ADHD questionnaires.
For participants using medication, ratings of participants function-
ing were done off medication. All participants were administered
the Dutch translation of the Schedule for Affective Disorders and
Schizophrenia for School-Age Children-Present and Lifetime Version
(Kaufman et al., 1997), carried out by trained professionals. Both
the parents and the participant, if Z12 years old, were inter-
viewed separately and were initially administered the ADHD screen-
ing interview. Participants with elevated scores on any of the
screening items were administered the full ADHD section. In
addition, each participant was assessed with a parent-ratedquestionnaire (Conners' Parent Rating Scale-Revised: Long version,
Conners et al., 1998b) combined with either a teacher-rated
questionnaire for childreno18 years (Conners' Teacher Rating
Scale-Revised: Long version; Conners et al., 1998a) or a self-
report questionnaire for participantsZ18 years (Conners' Adult
ADHD Rating Scales-Self-Report: Long version; Conners et al.,
1999). Participants with Zsix symptoms of hyperactive/impulsive
behavior and/or inattentive behavior were diagnosed with ADHD,
provided they: a) met the DSM-IV criteria for pervasiveness and
impact of the disorder; b) had an onset-age before 12, and c) scored
TZ63 on at least one of the ADHD scales on either one of the
Conners' ADHD questionnaires. Healthy control participants were
required to score To63 on each of the ADHD scales of each of the
Conners’ questionnaires, and have r3 combined symptoms. Cri-
teria were adapted for participants of 18 years or older, such that
ﬁve symptoms were sufﬁcient for a diagnosis andrtwo symptoms
were allowed for healthy control participants. Additional assess-
ments included the Children’s Social Behavior Questionnaire
(Hartman, et al., 2006) to measure symptoms of autism spectrum
disorders, the block-design and vocabulary subtests of the Wechsler
Intelligence Scale for Children (Wechsler, 2002) for participants
o18, or the Wechsler Adult intelligence Scale (Wechsler, 2000) for
participants Z18 to estimate IQ, and the Children’s Global Assess-
ment Scale (Shaffer et al., 2014) to assess functional impairment in
daily life.
2.3 Assessment of medication history
All participants provided written consent to obtain lifetime medi-
cation transcripts from the pharmacy. For participants under the
age of twelve, permission was obtained from one or both of the
parents. In addition, an extensive questionnaire was used to assess
lifetime history of psychoactive medication for all participants. The
questionnaire was administered during the testing day, either by
the parents or by the participant (4age 18). For healthy control
participants, the pharmacy transcripts and questionnaires were
used to ascertain a negative history of any type of psychoactive
medication. For participants with ADHD, cumulative stimulant
intake was calculated from the pharmacy transcripts as the lifetime
total stimulant dose in mg. Dexamphetamine dose was multiplied
by two in this calculation. If pharmacy transcripts did not cover the
medicated period according to the medication questionnaire
(n=48, 29%), stimulant intake during the missing period(s) were
calculated from the questionnaire data, and were added to the
cumulative intake derived from the pharmacy data. Cumulative
stimulant intake was divided by participant's age minus 2.3 (the
minimum stimulant start age within our sample), to obtain a
measure of cumulative intake independent of age (CSI), which
was used in all analyses.
2.4 MRI acquisition
Participants were asked to withhold use of psychoactive drugs for 48 h
before scanning. MRI data was acquired at 1.5 T on a Siemens Sonata
scanner at the VU Medical Center (Amsterdam, the Netherlands) and on
a Siemens Avanto scanner at the Donders Center for Cognitive
Neuroimaging, (Nijmegen, the Netherlands). An identical 8-channel
phased array coil was used at both sites and all scan parameters were
matched as closely as possible. The scan protocol included one eddy-
current compensated diffusion-weighted SE-EPI sequence (5 volumes
without directional weighting, followed by 60 diffusion-weighted
volumes of 60 interleaved transverse slices each, slice thickness
2.2 mm, FOV=256 mm, TR=8500 ms, TE=97 ms; b-value=1000 s/
mm2, GRAPPA-acceleration 2), and two T1-weighted MP-RAGE scans
(TI=1000 ms, TR=2730 ms, TE=2.95 ms, FA=71; 176 sagittal slices,
voxel size 1 1 1 mm3, FOV=256 256 176 mm3; GRAPPA
acceleration 2).
Figure 1 Study-speciﬁc white matter tractography masks, projected on the study-speciﬁc standard brain template. Coordinates
are in MNI-space. A. orbitofrontal-striatal tract (red), orbitofrontal-amygdalar tract (pink) and amygdalar-striatal tract (green;
X=26, Y=0, Z=14) B. dorsolateral-prefrontal-striatal tract (light blue; X=32, Y=14, Z=16) C. medial-prefrontal-striatal tract
(dark blue; X=16, Y=36, Z=2). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the
web version of this article.)
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For each subject, residual eddy current correction and realignment
of all denoised diffusion-weighted images per subject were per-
formed in SPM8 (Wellcome Trust Center for Neuroimaging). Denois-
ing was performed using a local PCA procedure and a dedicated
robust estimation algorithm (PATCH; Zwiers, 2010) was used to
correct for motion-induced artifacts and tensor estimation. Rea-
lignment parameters were comparable for participants with and
without ADHD, indicating similar levels of motion-distortion in the
two groups. B0 diffusion images of each participant were registered
to their own T1 structural scan, which in turn was registered to the
a 2 mm template (speciﬁc for NeuroIMAGE sample) using FNIRT in
FSL, creating warp ﬁelds to transform images from subject space to
standard space and vice versa.
First, the following masks were created from the AAL atlas in
standard space: left and right dorsolateral prefrontal cortex (dlPFC;
AAL 7+11+13 and 8+12+14), left and right medial prefrontal cortex
(mPFC; AAL 23 and 24), left and right orbitofrontal cortex (OFC; AAL 5
+9+15+25+27 and 6+10+16+26+28), left and right striatum (AAL
71+73 and 72+74), and left and right amygdala (AAL 41 and 42). Three
additional exclusion masks were registered: Xo1 (excluding the left
hemisphere), X41 (excluding the right hemisphere) and Yo30
(excluding all voxels posterior to the tail of the caudate nucleus).
Next, all masks were inversely warped to subject space and used to
specify in- and exclusion criteria for reconstructed white matter tracts.
The probtrackx2 tool in FSL performed probabilistic tractography
propagating 5000 streamlines per voxel within the seed mask, including
all streams that reach the waypoint-mask, and excluding all streamsthat ran through an exclusion-mask. The following white matter tracts
were reconstructed for each hemisphere: dorsolateral-prefrontal-
striatal (seed=dlPFC; waypoint=striatum), medial-prefrontal-striatal,
(seed=mPFC; waypoint=striatum), orbitofrontal-striatal, (seed=OFC;
waypoint=striatum), orbitofrontal-amygdalar (seed=amygdala; way-
point=OFC), and amygdalar-striatal (seed=amygdala; waypoint=stria-
tum). All ROI-masks other than the seed- and waypoint-mask were
speciﬁed as exclusion masks. Resulting distribution images were
thresholded to include only voxels that were hit by at least 1% of all
streamlines generated by probtrackx, and binarized to create a
subject-speciﬁc mask of each white matter tract. These maps were
then warped to standard space, summed up across all subjects,
thresholded such that voxels were included if at least 75% of all
subjects had a white matter tract in that voxel, and binarized to create
a study-speciﬁc mask of each white matter tract in standard space
(Figure 1). Last, FA and MD images of each participant were warped to
standard space, and FA and MD within each tract-mask were extracted.
For each tract we calculated left, right, and average FA and MD. For
follow-up analyses we also warped axial diffusivity (AD) and radial
diffusivity (RD) maps to standard space and extracted average AD and
RD for each tract and participant.
2.6 Statistical analyses
Statistical analyses were performed in SPSS version 22.0.0.0 (IBM,
2011). First, we compared average FA and MD within each white
matter tract between participants with ADHD and healthy control
participants using General Linear Mixed (GLM) modeling, taking into
account gender, scanner site, age, and age-squared and including a
L.J.S. Schweren et al.678random intercept to account for the clustered family data. We also
examined possible interaction effects between diagnosis and age,
age-squared, and gender. Second, the same statistical model was
applied to investigate the effect of CSI on FA and MD (only within
participants with ADHD), as well as possible interaction effects
between CSI and age, age-squared, and gender. For the within-
ADHD analyses, participants with missing stimulant treatment data
(n=8) were excluded, as well as one participant who was an outlier
on cumulative stimulant intake (z=5.6).
We applied a two-step method to correct for multiple compar-
isons. Given that we had ﬁve positively correlated tracts per DTI-
measure, we ﬁrst calculated the effective number of tests (Meff;
Moskvina and Schmidt, 2008) based on bivariate correlations
between the ﬁve outcome measures (ranging from r=0.185 to
r=0.887). Next, Meff was applied to the Dunn-Sidak familywise error
rate correction (Šidàk, 1967). For the analyses of FA and MD, Meffs
were 3.81 and 3.40, and the adjusted alpha-levels derived from
Dunn-Sidak-correction were 0.013 and 0.015, respectively.
Signiﬁcant effects of treatment or diagnosis were ensued by
follow-up analyses: (1) analyzing the left and right hemisphere
separately, (2) analyzing AD and RD separately, and (3) adding to
the model any clinical or demographic variable that was associated
with CSI, as these may have been confounders (for treatment
effects). The same adjusted alpha-levels were used in the follow-up
analyses. Last, we tested the robustness of our ﬁndings by repeating
our analyses within various subsamples, namely boys (n=172) and
girls (n=96), participants who had been tested in Nijmegen
(n=143) and in Amsterdam (n=125), participants with no history
of dexamphetamine treatment (n=249), and participants stratiﬁed
into age quartiles (no14.96=67, n14.9617.50=67, n17.50–19.57=68,














Stimulant age of initiation (years)* 8.66 2.63




Stimulant mean daily dose (mg) 31.31 16.06
*within participants who had received stimulant treatment
(n=145).
†within participants who had ceased treatment43 months
prior to scanning (n=98).3 Results
The ADHD and control samples did not differ in age (HC:
M=16.96, SD=3.26; ADHD: M=17.39, SD=3.05; t=1.096,
p=0.274), gender (HC: NMALE=56, 58%; ADHD: NMALE=116,
67%; Chi2=2.223, p=0.136), or scanner location (HC:
NNIJMEGEN=44, 46%; ADHD: NNIJMEGEN=99, 58%; Chi
2=3.403,
p=0.065). Participants with ADHD had lower IQ (HC:
M=106.47, SD=14.09; ADHD: M=96.62, SD=13.67;
t=5.582; p=0.001) compared to control participants. The
difference in IQ was considered part of the ADHD phenotype
(Dennis et al., 2009), thus IQ was not added as a covariate.
Cumulative stimulant intake was available for 163 parti-
cipants with ADHD. Participants had inattentive type (n=82,
50%), combined type (n=66, 41%), or hyperactive type
ADHD (n=15, 9%). Thirty-two percent (n=52) had a co-
morbid diagnosis, mostly oppositional deﬁant disorder or
conduct disorder (n=47, 29%), but also tic disorders (n=3%,
2%) and anxiety/depression (n=4, 3%). Treatment charac-
teristics of the ADHD group are summarized in Table 1. The
vast majority had at some point in their lives been treated
with stimulants, including immediate release methylpheni-
date (n=141, 87%), extended-release methylphenidate
(n=112, 69%), and dexamphetamine (n=18, 11%). Average
cumulative stimulant intake was 62,396 mg (equal to
5.7 years of 30 mg per day), ranging from zero mg (stimu-
lant-naïve) to 289,000 mg (equal to 13.2 years of 60 mg per
day). Forty percent (n=65) of participants with ADHD had
received stimulant treatment within three months prior to
scanning; the other participants had ceased treatment prior
to study participation. Psychoactive medication other thanstimulants was frequent, and included atomoxetine (n=20,
12%), atypical antipsychotics (n=22, 14%), benzodiazepines
(n=10, 6%), and antidepressants (n=7, 4%%). Individual
differences in clinical characteristics or stimulant treatment
history (other than CSI) were analyzed as potential con-
founders (see below).
3.1 Participants with ADHD vs. healthy control
participants
Compared to healthy control participants, participants with
ADHD had lower FA in white matter tracts connecting the
striatum and the orbitofrontal cortex (Cohen's d=0.269,
p=0.010). The direction of effect remained unchanged
when participants were stratiﬁed by gender, scanner site,
or age quartiles, and when participants treated with
dexamphetamine preparations were excluded (e-Supple-
ment I, available online). Follow-up analyses showed that
lower OFC-striatal FA was present in both hemispheres, and
signiﬁcant after correction for multiple testing in the left
hemisphere. There were no case-control differences in axial
(p=0.132) or radial diffusivity (p=0.218) in this pathway.
Lower FA in the dorsolateral-prefrontal-striatal pathway
was nominally signiﬁcant, but failed to reach the alpha-
level adjusted for multiple testing (Cohen's d=0.289,
p=0.018). In the mPFC-striatal tract, amygdalar-striatal
tract, and the OFC-amygdalar tract we found no FA differ-
ences between participants with ADHD and healthy controls
(Table 2). Further, we found no diagnosis-by-gender
(p40.432), diagnosis-by-age (p40.128), or diagnosis-by-
age-squared (p40.289) interaction effects on FA in
any tract.
There were no between-group differences in MD in any of
the tracts (p40.503, Table 2). Moreover, we found no
diagnosis-by-gender (p40.142), diagnosis-by-age (p40.490),
or diagnosis-by-age-squared (p40.186) interaction effects on
MD. Finally, across all participants, FA and MD were negatively
Table 2 Main effects of diagnosis (ADHD or healthy control) on FA and MD for each tract.
FA MD
b p Sign b p Sign
OFC – Striatum 0.008 0.010 ** 0.001 0.876
Right 0.008 0.032 *
Left 0.008 0.009 **
dlPFC – Striatum 0.008 0.018 * o0.001 0.951
mPFC – Striatum o0.001 0.912 o0.001 0.910
Amygdala – Striatum 0.004 0.253 0.001 0.880
OFC – Amygdala 0.001 0.617 0.003 0.503
*po0.05;
**signiﬁcant after correction for multiple testing, αFA=0.013, αMD=0.015.
Positive b-values indicate reduced FA/MD in participants with ADHD compared to healthy controls. Abbreviations: FA, fractional
anisotropy; MD, mean diffusivity; OFC, orbitofrontal cortex; dlPFC, dorsolateral prefrontal cortex; mPFC, medial prefrontal cortex.
Table 3 Main effects of age-independent cumulative stimulant intake on FA and MD for each tract.
FA MD
b p Sign b p Sign
OFC –
Striatum
0.001 0.501 0.005 0.011 **
Right 0.006 0.016 *
Left 0.004 0.027 *
mPFC –
Striatum
0.001 0.713 0.005 0.021 *
OFC –
Amygdala
0.001 0.389 0.005 0.016 *
dlPFC–
Striatum
0.001 0.713 0.004 0.055
Amygdala –
Striatum
0.002 0.355 0.003 0.119
*po0.05;
**signiﬁcant after correction for multiple testing, αFA=0.013, αMD=0.015.
Positive b-values indicate reduced FA/MD in participants with ADHD compared to healthy controls. Abbreviations: FA, fractional
anisotropy; MD, mean diffusivity; OFC, orbitofrontal cortex; dlPFC, dorsolateral prefrontal cortex; mPFC, medial prefrontal cortex.
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po0.001), but not in the other tracts.3.2 Cumulative stimulant treatment
Within the ADHD group, CSI did not predict FA values in any
of the white matter tracts (p40.355, Table 3). Further-
more, there were no CSI-by-gender (p40.103), CSI-by-age
(p40.060), or CSI-by-age-squared (p40.293) interaction
effects on FA. Cumulative stimulant intake was negatively
associated with MD in orbitofrontal-striatal pathway
(Cohen’s d=0.164, p=0.011). The direction of effect
remained unchanged when participants were stratiﬁed by
gender, scanner site, or age quartiles, and when partici-
pants treated with dexamphetamine preparations were
excluded (e-Supplement I, available online). Follow-up
analyses revealed that higher CSI was associated with lowerMD in both hemispheres, and that higher CSI was associated
with lower AD (Cohen's d=0.107, p=0.046) and lower RD
(Cohen's d=0.165, p=0.029). None of the follow-up
analyses reached the alpha-level adjusted for multiple
testing (α=0.015). In addition, we found nominally signiﬁ-
cant lower MD in the orbitofrontal-amygdalar (Cohen's
d=0.120, p=0.016) and medial-prefrontal-striatal path-
ways (Cohen's d=0.188, p=0.021), but neither met the
adjusted alpha-level. CSI was not associated with MD in the
dlPFC-striatal or amygdalar-striatal tracts (Table 3). There
were no CSI-by-gender interaction effects (p40.115), CSI-
by-age (p40.368) or CSI-by-age-squared (p40.350) inter-
action effects on MD. Within participants with ADHD, there
was a negative correlation between FA and MD in the mPFC-
striatal tract (Pearson's r=0.211, p=0.007), but not in the
other tracts.
Cumulative stimulant intake was positively correlated with
the number of ADHD symptoms (r=0.271, p=0.001), and was
L.J.S. Schweren et al.680different for the three ADHD types (F=8.380, p=0.001). CSI
was higher in the combined type group compared to the
hyperactive group (mean COMBINED=14.6,mean HYPERACTIVE=5.9,
p=0.007) and to the inattentive group (mean COMBINED=14.6,
mean INATTENTIVE=8.8, p=0.002). CSI was not related to
functioning in daily life (p=0.325), presence of co-morbid
disorders (p=0.291), treatment with non-stimulant ADHD med-
ication (p=0.730), treatment with medication other than for
ADHD (p=0.206), or symptoms of autism spectrum disorder
(p=0.258). The analyses of orbitofrontal-striatal MD were
repeated including the number of ADHD symptoms as a
covariate. Number of symptoms did not predict orbitofrontal-
striatal MD (p=0.360). Adding the number of symptoms to the
model caused the effect of CSI to fall short of signiﬁcance,
although the size of the effect changed little (Cohen's
d=0.144, p=0.036). Similarly, ADHD type, added to the
model as two dummy variables, did not predict OFC-striatal MD
(p COMBINED vs. HYPERACTIVE=0.090; p COMBINED vs. INATTEN-
TIVE=0.109), but adding this covariate caused the effect of
CSI to fall short of signiﬁcance (Cohen's d=0.114, p=0.094).
These analyses indicate that although ADHD severity, ADHD
type, and stimulant exposure are overlapping (resulting in
larger standard errors of the estimated regression coefﬁcients
when modeled simultaneously, reducing statistical signiﬁ-
cance), this overlap has little impact on the effect size of
the association between orbitofrontal-striatal MD and CSI.4. Discussion
The current study investigated associations between stimu-
lant treatment history and white matter microstructural
abnormalities in frontal-striatal and mesolimbic pathways,
in a large sample of children, adolescents, and young adults
with ADHD. We had hypothesized that FA would be lower
and MD would be higher, both indicative of impaired
structural connectivity, in participants with ADHD compared
to healthy control participants. Indeed we found lower FA in
the orbitofrontal-striatal tracts in participants with ADHD.
There were no case-control differences in MD. Second, we
had hypothesized that white matter microstructural
abnormalities would be more prominent in participants with
ADHD who had received little or no stimulant treatment. We
found that cumulative stimulant intake was negatively
correlated with orbitofrontal-striatal MD, suggesting higher
structural connectivity with more and/or longer stimulant
treatment. We found no correlations between stimulant
treatment and frontal-striatal or mesolimbic FA.
Our ﬁndings are in line with those of De Luis-Garcia et al.
(2015), who found lower MD in children who had been
treated with stimulants compared to those who had not. In
their sample, lower MD in stimulant-treated children was
present in white matter tracts connecting the orbitofrontal
cortex, and this was not accompanied by higher FA. The
interpretation of subtle FA and MD changes is equivocal.
Increased MD and decreased FA may be regarded as indica-
tions of impaired structural connectivity, and often, but not
always, co-occur (Thomason and Thompson, 2011). It
remains speculative, however, which neurodevelopmental
or neuropathological processes underlie such alterations in
FA and MD (Jones et al., 2013). Changes in FA and MD in
ADHD may represent two distinct mechanisms, i.e. reducedFA may represent a familiar (e.g. genetic) vulnerability to
ADHD, whereas MD may be a clinical state marker (Van
Ewijk et al., 2014). The current associations between
stimulant treatment and orbitofrontal-striatal MD but not
FA are in line with this hypothesis. Alternatively, the
discrepancy between FA and MD ﬁndings could suggest that
stimulant treatment may interact with a non-dysfunctional
feature of white matter connectivity. We wish to addition-
ally emphasize that conﬁrmation in an independent sample
is needed to exclude the possibility of a Type 1 error thereby
avoiding over-interpretation, especially given the modest
effect size of the ﬁnding in MD.
Stimulant intake correlated with white matter abnorm-
alities in pathways connecting the orbitofrontal cortex to
the striatum, and, albeit only nominally signiﬁcant, to the
amygdala. Altered structural connectivity within
orbitofrontal-striatal pathways in individuals with ADHD
has been related to impulsivity (Konrad et al., 2010),
impaired school functioning (Wu et al., 2014) and neurop-
sychological deﬁcits (Shang et al., 2013). Very little is
known about the long-term effects (multiple years) of
stimulant treatment on either mesolimbic structures or on
behaviors mediated by these structures. In previous studies
of the current sample, we found no associations between
stimulant treatment and striatal or amygdalar volumes
(Greven et al., 2015) or orbitofrontal cortical thickness
(Schweren et al., 2015). Other structural and functional
neuroimaging studies, including a positron-emission tomo-
graphy (PET) study, have indicated long-term stimulant
treatment effects on the striatum and amygdala (Ludolph
et al., 2008; Onnink et al., 2013), but there have also been
null ﬁndings (Schlochtermeier et al., 2011; Stoy et al.,
2011). Like the current study, each of these studies in adults
has been observational and lacked pretreatment measure-
ment. Nevertheless, previous studies in conjunction with
the current study support the importance of the orbito-
frontal cortex and its striatal and limbic connections in
ADHD, and suggest that structural connectivity of the
orbitofrontal cortex may be affected by stimulant
treatment.
As we expected, stimulant treatment was positively
associated with ADHD severity: participants with a history
of higher cumulative stimulant intake presented with more
ADHD symptoms compared to patients with little or no
stimulant treatment history. Similarly, patients with differ-
ent ADHD types presented with different treatment his-
tories (i.e. higher stimulant intake in the combined group
compared to the hyperactive and inattentive groups).
Disentangling the individual contributions of stimulant
treatment and ADHD severity or type is a challenge.
Confounding by indication, where more severely affected
individuals are likely to receive more treatment, is inevi-
table when studying long-term treatment effects in chil-
dren. We attempted to address the confounding effect of
clinical differences by entering ADHD severity and ADHD
type as covariates in the model predicting MD from cumu-
lative stimulant intake. These clinical variables were mea-
sured post-treatment, thus at best representing a proxy of
pretreatment clinical differences. The treatment effect on
orbitofrontal-striatal MD changed little when differences in
ADHD severity and/or type were accounted for, i.e., the
effect was small with and without these additional
681Stimulant treatment history predicts frontal-striatal structural connectivity in adolescentscovariates. However, the effect was no longer signiﬁcant,
which indicates an increased standard error around the
estimated effect. When simultaneously analyzed, the effect
of treatment was more signiﬁcant than the effect of either
of the clinical variables (p=0.036 versus p=0.360 for
number of symptoms, and p=0.094 versus p=0.134 for
ADHD type), which indicates that stimulant treatment
history is an important predictor and more predictive than
ADHD severity or type. In addition, when ADHD severity and
type were each separately analyzed without cumulative
stimulant intake, neither signiﬁcantly predicted
orbitofrontal-striatal MD (data not shown). We conclude
that although confounding by indication cannot be
excluded, our ﬁndings support the importance of stimulant
treatment history for orbitofrontal-striatal MD.
The current study had the following limitations. Studies
investigating long-term treatment effects in children,
including the current study, are inevitably naturalistic by
design. In addition our study lacked pre-treatment assess-
ment. As a result, we cannot exclude the possibility that
white matter differences may have led to stimulant pre-
scription (possibly through more severe ADHD behavior)
instead of vice versa. Second, some regions of our interest,
including the orbitofrontal cortex, are relatively susceptible
to DTI scanning artifacts (e.g. image distortion). Conse-
quently, we used group templates of white matter tracts, as
opposed to using each participant’s individual tracts, which
resulted in relatively small study-speciﬁc regions of interest
per white matter tract. ROI selection of frontal-striatal
pathways also precluded ﬁnding potential changes in other
white matter pathways affected by non-dopaminergic sti-
mulant effects. For example, noradrenergic stimulant
effects are known to occur both within and beyond the
PFC, and may result in white matter changes in the poster-
ior lobes and cerebellum that were not studied here.
Finally, performing tractography using masks of functionally
deﬁned striatal subregions (e.g., Di Martino et al., 2008)
may in future studies enhance anatomical speciﬁcity of
white matter tracts, and aid in understanding behavioral
correlates of neural changes. There are several strengths to
our study as well. This is the ﬁrst study to date investigating
long-term stimulant effects on white matter integrity in a
large and representative ADHD sample. In addition, our
sample with its wide age-range allowed the investigation of
long-term treatment effects spanning multiple years. More-
over, using lifetime pharmacy transcripts stimulant treat-
ment history was assessed to a level of detail that has not
previously been achieved.
In conclusion, participants with ADHD showed white
matter microstructural abnormalities in orbitofrontal-
striatal pathways, and stimulant treatment was associated
with white matter microstructure in this same pathway.
Whereas stimulant treatment was related to MD, case-
control differences were found in FA but not MD. These
ﬁndings could be interpreted to suggest that differences in
FA and MD may represent two distinct pathophysiological
processes in ADHD, and/or that stimulant treatment may
act through enhancing a non-dysfunctional feature of white
matter connectivity. Both hypotheses need further investi-
gation in independent samples. Our ﬁndings support the
importance of the orbitofrontal cortex and its connections
in the pathophysiology of ADHD.Role of funding source
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